Table 2.
Comparison of efficacy outcomes in matched patients who were previously naïve to blinatumomab and inotuzumab in ZUMA-3 and SCA-1
| Blinatumomab and inotuzumab-naïve patients | ||
|---|---|---|
| ZUMA-3 matched patients (n = 20) | SCA-1* (n = 20) |
|
| Overall CR/CRi rate, % (95% CI) | 85.0 (62.1–96.8) | 35.0 (15.4–59.2) |
| CR rate | 75.0 (50.9–91.3) | 30.0 (11.9–54.3) |
| Treatment difference (95% CI) | 50.0 (17.9–73.7) | |
| Odds ratio (95% CI) | 10.5 (2.3–48.7) | |
| p value | 0.0031 | |
| AlloSCT rate, % (95% CI) | 35.0 (15.4–59.2) | 20.0 (5.7–43.7) |
| Treatment difference (95% CI) | 15.0 (-13.7–42.4) | |
| Odds ratio (95% CI) | 2.2 (0.5–9.0) | |
| p value | 0.4801 | |
| Median RFS (95% CI), months | 20.5 (2.8–NE) | 0.0 (0.0–4.6) |
| Hazard ratio (95% CI) | 0.18 (0.1–0.5) | |
| p value | 0.0004 | |
| Median OS (95% CI), months | NR (18.2–NE) | 5.5 (1.9–12.1) |
| Hazard ratio (95% CI) | 0.15 (0.1–0.5) | |
| p value | 0.0001 | |
*SCA-1: SCHOLAR-3 patients who were previously naïve to blinatumomab and inotuzumab at enrollment in historical trials in which they may have received blinatumomab or inotuzumab
AlloSCT = allogeneic stem cell transplant. CI = confidence interval. CR = complete remission. CRi = complete remission with incomplete hematological recovery. NE = not estimable. NR = not reached. RFS = relapse-free survival. SCA = synthetic control arm